Announcements Trials

Browse Landscape

Phase

Status

Completed 3 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Frailty 3 Ovarian Neoplasms 2 Treatment Adherence and Compliance 1 Sarcopenia 1 Prostatic Neoplasms 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, B-Cell 1 Lymphoma 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hematopoietic and Lymphoid System Neoplasm 1 Hematologic Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 27 fludarabine 18 Rituximab 17 obinutuzumab 11 venetoclax 9 Bendamustine Hydrochloride 9 Lenalidomide 8 zanubrutinib 6 Prednisone 6 Doxorubicin 6 Blood Specimen Collection 6 pembrolizumab 5 fludarabine phosphate 5 Biopsy 5 ibrutinib 4 glofitamab 4 Vincristine 4 Trimethoprim, Sulfamethoxazole Drug Combination 4 Exercise 4 loncastuximab tesirine 3 gamma-Globulins 3 axicabtagene ciloleucel 3 acalabrutinib 3 Temozolomide 3 Surveys and Questionnaires 3 Palliative Care 3 Mycophenolic Acid 3 Methotrexate 3 Mesna 3 Magnetic Resonance Spectroscopy 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lymphoma × Geriatric Assessment × Clear all

NCT05006482 2026-01-13

GEM-S

University of Rochester

Phase 3 Recruiting

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡